Inhibitory effect of trimetazidine on utilization of myocardial glycogen during coronary ligation in dogs.
The left anterior descending coronary artery (LAD) of the dog was ligated completely for 1.5 min, and immediately after LAD ligation the heart was taken for determination of the glycogen phosphorylase and glycogen. Trimetazidine was injected intravenously 20 min before LAD ligation. LAD ligation increased the activity of glycogen phosphorylase and decreased the level of glycogen in both ischemic (LAD) and nonischemic (circumflex) areas. Trimetazidine at the dose of 0.3 or 1.0 mg/kg, being the dose that did not affect blood pressure and heart rate markedly, inhibited the ischemia-induced changes in glycogen phosphorylase and glycogen level. It is concluded that trimetazidine inhibits the ischemia-induced increase in the utilization of glycogen in the dog myocardium.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000378:metabolism* / Q000503:physiopathology; D003331:Coronary Vessels / Q000502:physiology; D004285:Dogs; D005260:Female; D006003:Glycogen / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D008026:Ligation; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D006005:Phosphorylases / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D014292:Trimetazidine / Q000494:pharmacology*
D010879:Piperazines; D006003:Glycogen; D006005:Phosphorylases; D014292:Trimetazidine